VolitionRx Limited

VolitionRx Limited is a multinational epigenetics company focused on advancing the science of epigenetics to revolutionize the diagnosis and monitoring of life-altering diseases. The company is dedicated to saving lives and improving outcomes for people and animals through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition develops and commercializes simple, easy-to-use, cost-effective blood tests designed to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's core technology platform is Nu.Q®, a groundbreaking nucleosome quantification technology. Nucleosomes are chromosomal structures that can serve as biomarkers, and Volition's patented technologies use nucleosomes and transcription factors to detect characteristic changes that occur from the earliest stages of disease. This enables early detection and potentially better monitoring of disease progression and a patient's response to treatment. The Nu.Q® platform is currently being used for cancer applications in veterinary medicine, and the company is expanding its technology into human medicine through early clinical trials in cancer, sepsis and beyond. Volition's product portfolio is organized around several pillars. Nu.Q® Cancer focuses on cancer detection and monitoring, with applications in lung cancer, non-Hodgkin lymphoma, ovarian cancer and other cancers. Nu.Q® NETs is a CE-marked diagnostic solution that clinicians can use to detect NETosis, a process implicated in sepsis and other conditions. Nu.Q® Vet is an affordable veterinary diagnostic offering for canine and feline cancer. Nu.Q® Discover supports research applications. The company also offers recombinant nucleosomes for research use. VolitionRx is headquartered in the United States and operates through subsidiaries in multiple countries, including Belgium, France, the United Kingdom and Singapore. The company is publicly listed on the NYSE American under the ticker symbol VNRX. Its executive team includes Cameron Reynolds as President and Group Chief Executive Officer, Terig Hughes as Group Chief Financial Officer, Gaetan Michel as Chief Operating Officer, Jake Micallef as Chief Scientific Officer, and other senior leaders. The company has a team of over 70 dedicated staff spanning a wide range of disciplines. In recent developments, Volition has participated in the launch of the DETECSEPS program in France, announced the pre-payment in full of a $7.5 million promissory note, presented early-stage solid cancer detection data at the ESMO MAP Conference, and announced clinical validation of its Nu.Q® NETs biomarker. The company continues to advance its Nu.Q® NETs platform towards commercialization and has filed new patents protecting its Nu.Q® NETs test. It has also announced a collaboration with Sysmex and published peer-reviewed papers on its Capture-Seq™ technology.

VolitionRx Limited was founded with the determination to transform lives on a global scale, a purpose reflected in its name: 'Volition' means to have determination and a purpose. The company was established to advance the science of epigenetics and revolutionize the way disease is diagnosed and monitored. Drawing inspiration from historic scientific breakthroughs such as penicillin, vaccines and genome editing, Volition set out to develop innovative diagnostic solutions that could detect diseases at their earliest stages. The company's foundational technology, Nucleosomics™, is based on the use of chromosomal structures such as nucleosomes and transcription factors as biomarkers. This patented approach enables the detection of characteristic changes that occur from the earliest stages of disease, allowing for early detection and potentially better monitoring of disease progression and treatment response. Over time, Volition developed its Nu.Q® platform, a groundbreaking nucleosome quantification technology that forms the basis of its product portfolio. Volition has grown into a multinational epigenetic company with subsidiaries operating in multiple countries, including Belgium, France, the United Kingdom and Singapore. The company's Nu.Q® technology is currently being used for cancer applications in veterinary medicine, with products such as Nu.Q® Vet for canine and feline cancer. In human medicine, Volition is expanding its technology through early clinical trials in cancer, sepsis and beyond. Its Nu.Q® NETs test is a CE-marked diagnostic solution that clinicians can use to detect NETosis, a process associated with sepsis and other conditions. The company has achieved several regulatory and commercial milestones. It has announced clinical validation of its Nu.Q® NETs biomarker, filed new patents protecting its Nu.Q® NETs test for sepsis, and published peer-reviewed papers on its Capture-Seq™ technology. Volition has also entered into collaborations, including one with Sysmex, and has participated in the launch of the DETECSEPS program in France, which focuses on sepsis detection. The company has presented data on early-stage solid cancer detection at the ESMO MAP Conference and has demonstrated the utility of rapid, point-of-care finger-prick detection of Nu.Q®. VolitionRx is publicly listed on the NYSE American under the ticker symbol VNRX. The company is headquartered in the United States and has a team of over 70 dedicated staff spanning a wide range of disciplines. Its executive team includes Cameron Reynolds as President and Group Chief Executive Officer, Terig Hughes as Group Chief Financial Officer, Gaetan Michel as Chief Operating Officer, Jake Micallef as Chief Scientific Officer, and other senior leaders. The board of directors includes Timothy I. Still as Chairman and several independent directors. The company continues to advance its mission to save lives and improve outcomes for people and animals with life-altering diseases through earlier detection and disease monitoring.

• VolitionRx Limited founded

• Development of Nucleosomics™ technology platform

• Launch of Nu.Q® Technology

• Nu.Q® NETs receives CE marking

• Commercialization of Nu.Q® Vet for veterinary cancer applications

• Announcement of clinical validation of Nu.Q® NETs biomarker

• Participation in launch of DETECSEPS program in France

• Pre-payment in full of $7.5 million promissory note

• Presentation of early Stage I solid cancer detection at ESMO MAP Conference

• Announcement of collaboration with Sysmex

• Publication of first peer-reviewed paper on Capture-Seq™ technology

VolitionRx positions itself as a multinational epigenetics company dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases through simple, easy-to-use, cost-effective blood tests based on its proprietary nucleosome quantification technology. The company emphasizes early detection to save lives and improve outcomes for people and animals.

• Nu.Q® Technology

  Groundbreaking nucleosome quantification technology used as a platform for diagnostic tests.

• Nu.Q® Cancer

  Cancer detection and monitoring tests for lung cancer, non-Hodgkin lymphoma, ovarian cancer and other cancers.

• Nu.Q® NETs

  CE-marked diagnostic solution for detecting NETosis, associated with sepsis and other conditions.

• Nu.Q® Vet

  Affordable veterinary diagnostic tests for canine and feline cancer.

• Nu.Q® Discover

  Research-use product pillar supporting epigenetics research.

• Recombinant Nucleosomes

  Recombinant nucleosomes available for research applications.

• Capture-Seq™

  New technology with first peer-reviewed paper published.

1. 1Volition - Early Diagnosis and Nucleosome Quantificationvolition.com
2. 2Our Company - Volitionvolition.com
3. 3Our Team - Volitionvolition.com
4. 4Resources - Volitionvolition.com
5. 5VolitionRx (United States) - Wikidatawikidata.org